[
  {
    "ts": "2025-10-14T18:41:51+00:00",
    "headline": "Johnson & Johnson’s (JNJ) Strong Dividend Track Record and Focus on Innovation",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 12 Reliable Dividend Stocks for Maximum Income. Johnson & Johnson (NYSE:JNJ) operates as a global healthcare lea‍de‌r, focusing p‌rimari​ly on pharmaceuticals and medi⁠cal d‍evices. Its⁠ operations are di‍vided into two main se⁠gment​s: Innovative Me⁠dicine, which de⁠velops and markets prescription drugs, and MedTech, which produces medi⁠cal d‌evic‌es. Up […]",
    "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-strong-dividend-184151668.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "22537d36-dca0-3286-b3f3-16e034f28d81",
      "content": {
        "id": "22537d36-dca0-3286-b3f3-16e034f28d81",
        "contentType": "STORY",
        "title": "Johnson & Johnson’s (JNJ) Strong Dividend Track Record and Focus on Innovation",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 12 Reliable Dividend Stocks for Maximum Income. Johnson & Johnson (NYSE:JNJ) operates as a global healthcare lea‍de‌r, focusing p‌rimari​ly on pharmaceuticals and medi⁠cal d‍evices. Its⁠ operations are di‍vided into two main se⁠gment​s: Innovative Me⁠dicine, which de⁠velops and markets prescription drugs, and MedTech, which produces medi⁠cal d‌evic‌es. Up […]",
        "pubDate": "2025-10-14T18:41:51Z",
        "displayTime": "2025-10-14T18:41:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Johnson & Johnson’s (JNJ) Strong Dividend Track Record and Focus on Innovation",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qG_90ptmVmYmlFzMjoC0Yw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q3JcjOP_BI3o_9_ANEkK.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-strong-dividend-184151668.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-strong-dividend-184151668.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "KVUE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-14T16:00:00+00:00",
    "headline": "Albert Invent Partners with Kenvue to Build the Future of Consumer Health Products With the Help of AI",
    "summary": "SUMMIT, N.J. & OAKLAND, Calif., October 14, 2025--Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Zyrtec®, Neutrogena®, and Listerine®, to accelerate end-to-end R&D efforts across the company’s global portfolio of brands. The partnership enables Kenvue to streamline, digitalize, and accelerate the end-to-end product lifecycle by leveraging Albert Invent's foundational AI models.",
    "url": "https://finance.yahoo.com/news/albert-invent-partners-kenvue-build-160000359.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "962ab974-dcc9-34ed-bab1-488d753394b3",
      "content": {
        "id": "962ab974-dcc9-34ed-bab1-488d753394b3",
        "contentType": "STORY",
        "title": "Albert Invent Partners with Kenvue to Build the Future of Consumer Health Products With the Help of AI",
        "description": "",
        "summary": "SUMMIT, N.J. & OAKLAND, Calif., October 14, 2025--Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Zyrtec®, Neutrogena®, and Listerine®, to accelerate end-to-end R&D efforts across the company’s global portfolio of brands. The partnership enables Kenvue to streamline, digitalize, and accelerate the end-to-end product lifecycle by leveraging Albert Invent's foundational AI models.",
        "pubDate": "2025-10-14T16:00:00Z",
        "displayTime": "2025-10-14T16:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/a61c3b4ba3b554edd99591def15564c6",
          "originalWidth": 2000,
          "originalHeight": 540,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RBAdcjWG3u7.HNygi4IKsQ--~B/aD01NDA7dz0yMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a61c3b4ba3b554edd99591def15564c6.cf.webp",
              "width": 2000,
              "height": 540,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1HUHbcJpn7Gy2V4wSHVyLg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a61c3b4ba3b554edd99591def15564c6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/albert-invent-partners-kenvue-build-160000359.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/albert-invent-partners-kenvue-build-160000359.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-14T13:20:35+00:00",
    "headline": "J&J lays out plan to splinter orthopedics business into separate company",
    "summary": "Johnson & Johnson is narrowing its focus again, nearly four years after peeling off its consumer health business.  The health care giant said Tuesday that it will separate its orthopedics business into a standalone company known as DePuy Synthes.  The move leaves J&J focused on its pharmaceutical and MedTech segments, which make prescription drugs, contact lenses and technology to treat cardiovascular disease and help with surgeries.",
    "url": "https://finance.yahoo.com/news/j-j-lays-plan-splinter-132035838.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "9e4d5c07-d729-3745-b0e5-46cb94e6972d",
      "content": {
        "id": "9e4d5c07-d729-3745-b0e5-46cb94e6972d",
        "contentType": "STORY",
        "title": "J&J lays out plan to splinter orthopedics business into separate company",
        "description": "",
        "summary": "Johnson & Johnson is narrowing its focus again, nearly four years after peeling off its consumer health business.  The health care giant said Tuesday that it will separate its orthopedics business into a standalone company known as DePuy Synthes.  The move leaves J&J focused on its pharmaceutical and MedTech segments, which make prescription drugs, contact lenses and technology to treat cardiovascular disease and help with surgeries.",
        "pubDate": "2025-10-14T13:20:35Z",
        "displayTime": "2025-10-14T13:20:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ap_finance_articles_694/85b721b86204850ff4931e5e238fd094",
          "originalWidth": 2780,
          "originalHeight": 1854,
          "caption": "FILE - A person walks by the Johnson & Johnson headquarters is in New Brunswick, N.J., on Feb. 8, 2024. (AP Photo/Ted Shaffrey, File)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ee9LdIiIhNU5zdb7Ee.P_g--~B/aD0xODU0O3c9Mjc4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/ap_finance_articles_694/85b721b86204850ff4931e5e238fd094.cf.webp",
              "width": 2780,
              "height": 1854,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p3mP3TpyEl1jApApgKb1cQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ap_finance_articles_694/85b721b86204850ff4931e5e238fd094.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/j-j-lays-plan-splinter-132035838.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-lays-plan-splinter-132035838.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "SN.L"
            },
            {
              "symbol": "KVUE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-14T12:43:00+00:00",
    "headline": "Johnson & Johnson Earnings Beat Estimates. Why the Stock Is Dropping.",
    "summary": "Johnson & Johnson  reported better-than-expected earnings Tuesday, while announcing it would spin off a slower-growing division within its medical devices segment that makes hip and knee implants.  Now, Johnson & Johnson plans to separate that business into a new company that will operate under the name DePuy Synthes.  While sales for Johnson & Johnson’s medical devices division grew 5.6% on an operational basis between the third quarter of 2024 and the third quarter of 2025, orthopaedics sales grew more slowly, up just 2.4% over the same period.",
    "url": "https://www.barrons.com/articles/johnson-johnson-earnings-jnj-stock-price-95523dd6?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "679a2f9a-5aca-3a2a-8bb6-3de1fb6df007",
      "content": {
        "id": "679a2f9a-5aca-3a2a-8bb6-3de1fb6df007",
        "contentType": "STORY",
        "title": "Johnson & Johnson Earnings Beat Estimates. Why the Stock Is Dropping.",
        "description": "",
        "summary": "Johnson & Johnson  reported better-than-expected earnings Tuesday, while announcing it would spin off a slower-growing division within its medical devices segment that makes hip and knee implants.  Now, Johnson & Johnson plans to separate that business into a new company that will operate under the name DePuy Synthes.  While sales for Johnson & Johnson’s medical devices division grew 5.6% on an operational basis between the third quarter of 2024 and the third quarter of 2025, orthopaedics sales grew more slowly, up just 2.4% over the same period.",
        "pubDate": "2025-10-14T12:43:00Z",
        "displayTime": "2025-10-14T12:43:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/679a2f9a-5aca-3a2a-8bb6-3de1fb6df007/johnson-johnson-earnings.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/90d6196d555c709904771580a5fe7e34",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QzY9AKsRjKPpaqJUuHbirg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/90d6196d555c709904771580a5fe7e34.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QfAW0SnRd723U8XuTnrzOw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/90d6196d555c709904771580a5fe7e34.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/johnson-johnson-earnings-jnj-stock-price-95523dd6?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-14T10:08:50+00:00",
    "headline": "Analysis-Trump's Tylenol claims limit M&A options for parent company Kenvue",
    "summary": "By Abigail Summerville and Svea Herbst-Bayliss (Reuters) -Tylenol maker Kenvue was already having a painful year before U.S. President Donald Trump and his health secretary got involved.",
    "url": "https://ca.finance.yahoo.com/news/analysis-trumps-tylenol-claims-limit-100850165.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "af054644-f4c9-3f35-82ae-0476f5e36063",
      "content": {
        "id": "af054644-f4c9-3f35-82ae-0476f5e36063",
        "contentType": "STORY",
        "title": "Analysis-Trump's Tylenol claims limit M&A options for parent company Kenvue",
        "description": "",
        "summary": "By Abigail Summerville and Svea Herbst-Bayliss (Reuters) -Tylenol maker Kenvue was already having a painful year before U.S. President Donald Trump and his health secretary got involved.",
        "pubDate": "2025-10-14T10:08:50Z",
        "displayTime": "2025-10-14T10:08:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/d55d525d431241c223ca064648c2f57b",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "The company logo for Kenvue Inc. Johnson & Johnson's consumer-health business, is displayed on during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023.  REUTERS/Brendan McDermid",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zBV4LTCSd9JzSvG4KKCm7w--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/d55d525d431241c223ca064648c2f57b.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K7mFXQpjOYfXfmmnefrfsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/d55d525d431241c223ca064648c2f57b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://ca.finance.yahoo.com/news/analysis-trumps-tylenol-claims-limit-100850165.html",
          "site": "finance",
          "region": "CA",
          "lang": "en-CA"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysis-trumps-tylenol-claims-limit-100850165.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-14T10:08:50+00:00",
    "headline": "Analysis-Trump's Tylenol claims limit M&A options for parent company Kenvue",
    "summary": "By Abigail Summerville and Svea Herbst-Bayliss (Reuters) -Tylenol maker Kenvue was already having a painful year before U.S. President Donald Trump and his health secretary got involved.",
    "url": "https://finance.yahoo.com/news/analysis-trumps-tylenol-claims-limit-100850165.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "af054644-f4c9-3f35-82ae-0476f5e36063",
      "content": {
        "id": "af054644-f4c9-3f35-82ae-0476f5e36063",
        "contentType": "STORY",
        "title": "Analysis-Trump's Tylenol claims limit M&A options for parent company Kenvue",
        "description": "",
        "summary": "By Abigail Summerville and Svea Herbst-Bayliss (Reuters) -Tylenol maker Kenvue was already having a painful year before U.S. President Donald Trump and his health secretary got involved.",
        "pubDate": "2025-10-14T10:08:50Z",
        "displayTime": "2025-10-14T10:08:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/e68942bba3b915b96d2c4da327a18214",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "The company logo for Kenvue Inc. Johnson & Johnson's consumer-health business, is displayed on during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023.  REUTERS/Brendan McDermid",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MgvS8Or1pvI3uQTCGd3DLA--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/e68942bba3b915b96d2c4da327a18214.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xqqH6iqyhgHGhRyLYGQ9dw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/e68942bba3b915b96d2c4da327a18214.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysis-trumps-tylenol-claims-limit-100850165.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysis-trumps-tylenol-claims-limit-100850165.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]